Innovation Panel Discussion Luncheon

As part of UO Startup Week, the Phil and Penny Knight Campus for Accelerating Scientific Impact and the Office of the Vice President of Research and Innovation will host a luncheon panel discussion with UO faculty who are actively engaged in the impact cycle, moving academic research findings into the commercial arena, and in some cases back to academic research laboratories.

Join us for a lively discussion on how to leverage the relationship between research and commercial engagement while enjoying a catered lunch. 

When: Noon to 1:30 p.m., Friday, November 16, 2018

Where: Redwood Room, Erb Memorial Union, University of Oregon

Reserve Free Tickets

 

 

 

Panelists

Janis Weeks

Janis Weeks

Janis Weeks, a professor emerita of biology at the University of Oregon, is the co-founder and chief global health officer of a University of Oregon spin-off company, NemaMetrix. Her extensive accomplishments in research and academia include applying neurophysiology and other techniques to the understanding of neural circuits and as a tool for drug development. Her more recent work focuses on parasitic diseases of humans and animals, pre-clinical models of human disease and technology development. She has leadership experience in diverse nonprofit organizations and more than 20 years of experience in neuroscience education and research capacity building in Africa.

Michael Marusich

Michael F. Marusich

Michael F. Marusich, PhD, a former Director of the University of Oregon Monoclonal Antibody Facility, is the founder of two UO spinoff companies. In 2011, he founded mAbDx, Inc., an immunodiagnostics company that has pioneered work on biomarkers of inflammation and infectious diseases, most recently to develop a simple hand-held test to diagnose Zika using a single drop of blood. Previously, Marusich co-founded MitoSciences along with UO professor Roderick Capaldi in 2003. MitoSciences was subsequently purchased by Abcam and is still considered a leading provider of anti-mitochondrial antibodies, assays and produced used world-wide in the study of mitochondria, metabolism and drug-induced mitotoxicity.

Eric Johnson

Eric Johnson

Eric Johnson is an associate professor of Biology and a member of the Institute of Molecular Biology. He has interests in genome sequencing technology and novel DNA sequencing methods. He was a co-founder of Floragenex in 2006, which commercialized the RAD-Seq method developed in his lab. More recently, he has been on leave to focus on the founding and operations of SNPsaurus, which has translated other methods from his lab to the market.

Robert Guldberg

Robert Guldberg

Robert Guldberg is vice president and Robert and Leona DeArmond Executive Director of the Phil and Penny Knight Campus for Accelerating Scientific Impact. Guldberg studies muscle and bone growth and development, focusing on potential regenerative therapies following traumatic injuries and in degenerative diseases such as osteoporosis and osteoarthritis. He is a co-founder of four start-up companies, most recently the medical device companies Restor3D and Vertera, which was acquired by NuVasive in October, 2017. Guldberg holds a number of patents and is very experienced in translating his work into innovations in the private sector.

moderator

Andrew Nelson

Andrew Nelson

Andrew Nelson is the Randall C. Papé Chair in Entrepreneurship and Innovation and associate professor of Management at the University of Oregon. He also serves as the University of Oregon's associate vice president for entrepreneurship and innovation and as academic director of the Lundquist Center for Entrepreneurship.

Nelson's research explores the development and commercialization of technological innovations, and has been featured both in leading academic journals and in international media outlets. An award-winning teacher, he is also the author of Technology Ventures: From Idea to Enterprise (McGraw-Hill), now in its 5th edition in multiple translations and used in entrepreneurship courses worldwide.